MedTrace Logo

Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

NCT02078089 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-01-31

No results posted yet for this study

Summary

This is an open-label, single arm, Phase Ib dose escalation study of Oxcarbazepine with morphine in patients with refractory cancer pain. The primary endpoint is to evaluate the safety and toxicity of the combination of Oxcarbazepine plus morphine. The secondary endpoints are improving pain control, reduce morphine use and improve the quality of life.

Conditions

Interventions

DRUG

Morphine

Morphine will be given to patients as part of their standard care

DRUG

Oxcarbazepine

Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.

Sponsors & Collaborators

  • Costantine Albany

    lead OTHER

Principal Investigators

  • Costantine Albany, M.D. · Indiana University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-06
Primary Completion
2014-12-11
Completion
2014-12-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02078089 on ClinicalTrials.gov